{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:39:33Z","timestamp":1792726773502,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.msard.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T02:30:56Z","timestamp":1483756256000},"page":"59-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"special_numbering":"C","title":["Classifying PML risk with disease modifying therapies"],"prefix":"10.1016","volume":"12","author":[{"given":"Joseph R.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib1","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain: J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.01.006_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jns.2015.04.010","article-title":"Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis","volume":"353","author":"Asztely","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2017.01.006_bib3","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1212\/NXI.0000000000000274","article-title":"Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate","volume":"3","author":"Baharnoori","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-107-1-78","article-title":"Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases","volume":"107","author":"Berger","year":"1987","journal-title":"Ann. Intern. Med."},{"issue":"Supplement 3","key":"10.1016\/j.msard.2017.01.006_bib6","first-page":"257","article-title":"A pilot study of recombinant alpha 2a interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy","volume":"42","author":"Berger","year":"1992","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2017.01.006_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"1","author":"Berger","year":"2009","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2017.01.006_bib9","unstructured":"Biogen, 2016a. Internal data on file."},{"key":"10.1016\/j.msard.2017.01.006_bib10","unstructured":"Biogen,\u00a02016b. TECFIDERA (Dimethyl fumarate): PML Case Reports. Retrieved October 3, 2016, from \u3008https:\/\/medinfo.biogen.com\/\u3009"},{"issue":"20","key":"10.1016\/j.msard.2017.01.006_bib11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2017.01.006_bib12","unstructured":"Brassat, D., 2016. Genomics biomarkers associated with the development of PML (Abstract157). ECTRIMS, London."},{"issue":"2","key":"10.1016\/j.msard.2017.01.006_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks","year":"1984","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2017.01.006_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s13365-016-0482-z","article-title":"Satatistical analysis of PML incidences of natalizujab-treated patietns from 2009 to 2016: outcomes after introduction of the stratify JCV DxSelect antibody assay","author":"Campagnolo","year":"2016","journal-title":"J. Neurovirol."},{"issue":"6","key":"10.1016\/j.msard.2017.01.006_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","article-title":"A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Chahin","year":"2015","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2017.01.006_bib16","series-title":"Teriflunomide Real-World Safety Profile: Results of the Phase 4 Teri-PRO Study","first-page":"P648","author":"Coyle","year":"2016"},{"issue":"10","key":"10.1016\/j.msard.2017.01.006_bib17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"Cutter","year":"2014","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.1108","article-title":"Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma","volume":"67","author":"Daibata","year":"2001","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.msard.2017.01.006_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12883-015-0363-8","article-title":"Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate","volume":"15","author":"Dammeier","year":"2015","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13550280601094563","article-title":"JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls","volume":"13","author":"Delbue","year":"2007","journal-title":"J. Neurovirol."},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ene.12834","article-title":"Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients","volume":"23","author":"Dominguez-Mozo","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejim.2008.07.032","article-title":"Progressive multifocal leukoencephalopathy, a review and an extended report of five patients with different immune compromised states","volume":"20","author":"Epker","year":"2009","journal-title":"Eur. J. Intern. Med."},{"issue":"5","key":"10.1016\/j.msard.2017.01.006_bib23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000069082","article-title":"\"Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin TNF-Alpha IL-10","volume":"49","author":"Gbadamosi","year":"2003","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.msard.2017.01.006_bib25","unstructured":"Genzyme, S., 2016. Internal data on file."},{"issue":"7","key":"10.1016\/j.msard.2017.01.006_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib28","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1212\/NXI.0000000000000085","article-title":"Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis","volume":"2","author":"Hoepner","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.msard.2017.01.006_bib29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1212\/WNL.41.11.1733","article-title":"Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data","volume":"41","author":"Holman","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.01.006_bib30","first-page":"2014","article-title":"Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab","author":"Isidoro","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2017.01.006_bib31","series-title":"Biologics in General Medicine","article-title":"Efalizumab: antibody characteristics, mode of action and preclinical development","author":"Jahn","year":"2007"},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0317167100012105","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"38","author":"Keene","year":"2011","journal-title":"Can. J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.msard.2015.05.003","article-title":"The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk","volume":"4","author":"Khatri","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00415-014-7620-4","article-title":"Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy","volume":"262","author":"Lehmann","year":"2015","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/WNL.0000000000002900","article-title":"PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter?","volume":"87","author":"Lehmann-Horn","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.01.006_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1128\/CMR.5.1.49","article-title":"Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"5","author":"Major","year":"1992","journal-title":"Clin. Microbiol. Rev."},{"issue":"9","key":"10.1016\/j.msard.2017.01.006_bib41","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/JVI.03221-13","article-title":"Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy","volume":"88","author":"Marshall","year":"2014","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.msard.2017.01.006_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib43","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1212\/NXI.0000000000000223","article-title":"Natalizumab-induced POU2AF1\/Spi-B upregulation: a possible route for PML development","volume":"3","author":"Meira","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2017.01.006_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13365-012-0107-0","article-title":"Disease-modifying drugs for multiple sclerosis and JC virus expression","volume":"18","author":"Miller","year":"2012","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2017.01.006_bib45","unstructured":"Novartis, 2016. Internal data on file."},{"issue":"6","key":"10.1016\/j.msard.2017.01.006_bib46","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2017.01.006_bib47","series-title":"Age of Natalizumab Start is a Risk Factor for Developing Early Onset Progressive Multifocal Leukoencephalopathy (PML)","first-page":"P1598","author":"Prosperini","year":"2016"},{"issue":"11","key":"10.1016\/j.msard.2017.01.006_bib48","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archneur.65.11.1538","article-title":"Leflunomide-associated progressive multifocal leukoencephalopathy","volume":"65","author":"Rahmlow","year":"2008","journal-title":"Arch. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2017.01.006_bib49","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2017.01.006_bib50","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.jid.5700996","article-title":"Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression","volume":"128","author":"Rubant","year":"2008","journal-title":"J. Investig. Dermatol."},{"issue":"9","key":"10.1016\/j.msard.2017.01.006_bib51","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/j.1432-2277.2012.01511.x","article-title":"Progressive multifocal leuko-encephalopathy after ABO-incompatible kidney transplantation","volume":"25","author":"Sanders","year":"2012","journal-title":"Transpl. Int"},{"issue":"11","key":"10.1016\/j.msard.2017.01.006_bib52","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pds.3320","article-title":"Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US adverse event reporting System (AERS)","volume":"21","author":"Schmedt","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"8","key":"10.1016\/j.msard.2017.01.006_bib53","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and L-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2017.01.006_bib54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","article-title":"Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab","volume":"77","author":"Villar","year":"2015","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2017.01.006_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.healun.2008.12.010","article-title":"Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant","volume":"28","author":"Waggoner","year":"2009","journal-title":"J. Heart Lung Transpl."},{"key":"10.1016\/j.msard.2017.01.006_bib56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneurol.2013.95","article-title":"Modulation of IL-2R\u03b1 with daclizumab for treatment of multiple sclerosis","volume":"9","author":"Weindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2017.01.006_bib57","doi-asserted-by":"crossref","DOI":"10.1007\/s13365-016-0449-0","article-title":"Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus","author":"Werner","year":"2016","journal-title":"J. Neurovirol."},{"issue":"9","key":"10.1016\/j.msard.2017.01.006_bib58","doi-asserted-by":"crossref","first-page":"e0136046","DOI":"10.1371\/journal.pone.0136046","article-title":"CRISPR\/Cas9 system as an agent for eliminating polyomavirus JC infection","volume":"10","author":"Wollebo","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.msard.2017.01.006_bib59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther. Adv. Drug Saf."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481730007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481730007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:39:23Z","timestamp":1761899963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481730007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":59,"alternative-id":["S221103481730007X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.01.006","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classifying PML risk with disease modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}